ACHN 2017 Annual Report

Achillion Pharmaceuticals, Inc. Statements of Comprehensive Loss (in thousands, except per share amounts) Years Ended December 31, 2017 2016 2015 Revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ — $ 15,000 $ 66,122 Operating expenses Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65,052 59,162 56,553 General and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24,524 20,703 24,676 Total operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89,576 79,865 81,229 Loss from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (89,576) (64,865) (15,107) Other income (expense) Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,390 3,227 1,188 Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (50) (68) (55) Other income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — 8,944 Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (85,236) $ (61,706) $ (5,030) Unrealized income (loss) on marketable securities . . . . . . . . . . . . . . (540) 196 (33) Total other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . (540) 196 (33) Total comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . $ (85,776) $ (61,510) $ (5,063) Basic and diluted net loss per share attributable to common stockholders (Note 4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (0.62) $ (0.45) $ (0.04) Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders . . . . . . . . . . . . . . . . . . . . . . . . . . 137,180 136,667 125,592 The accompanying notes are an integral part of these financial statements. F-5